Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Gwolf who wrote (1016)	6/17/1998 2:05:00 PM
From: drdan	Read Replies (1) \| Respond to of 5402

I agree thaT some competitors have a chance to field a product. I musthave not made myself clear. I was only tryig to point out that Sanguines prduct has a considerable advantage over others in that it is not hemoglobin based(therefore cheaper to produce and less likelyto scare the public),and has set a precedent for some degree of safety AND success in humans that the other products don't seem to have accomplished at this point. If I appear to be unreasonably hyping the company, I am sorry. This a wide open market but Sanguine has a good head start and should capture a big chunk of the market if trials are successful.Certainly not 90% or 100%, though....Until significant progress occurs in the development of hemoglbin based products, (eg,better safety, stability and expense),Sanguine SEEMS to stand alone.... Do your homework before plunking down your dollars....